Voyager Therapeutics Inc
Research Voyager Therapeutics Inc (VYGR) on Bullrun: market cap USD 213.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVYGR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 213.23M
- Financial periodQ2 2026
- RevenueUSD 3.17M
- Net income-USD 24.47M
- Free cash flow-USD 25.84M
Valuation Snapshot
latest market cap is USD 213.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 40.37M | -USD 119.72M | -USD 135.06M | n/a | -2.04 | USD 65.30M | USD 36.50M | USD 196.08M |
| FY2024 | USD 80.00M | -USD 65.00M | -USD 18.83M | n/a | -1.13 | USD 71.37M | USD 43.73M | USD 299.76M |
| FY2023 | USD 250.01M | USD 132.33M | USD 74.66M | n/a | 2.97 | USD 68.80M | USD 20.29M | USD 236.32M |
| FY2022 | USD 40.91M | -USD 46.41M | -USD 15.00M | n/a | -1.21 | USD 98.96M | USD 24.27M | USD 59.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 213.23M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 232.06M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 310.33M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 371.37M | 6.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 235.50M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 102.76M | n/a | n/a | n/a |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Voyager Therapeutics Inc's market cap?
Voyager Therapeutics Inc's market capitalization is USD 213.23M.
What does Voyager Therapeutics Inc do?
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease.